Featured Research

from universities, journals, and other organizations

Promising New TB Drug Given Special Status By US And European Regulators

Date:
October 25, 2007
Source:
NIH/National Institute of Allergy and Infectious Diseases
Summary:
SQ109, an antimicrobial agent has recently been granted 'orphan drug' status by the US Food and Drug Administration and the European Medicines Agency for development against drug-susceptible and drug-resistant TB. Approximately one-third of the world's population is infected with Mycobacterium tuberculosis, the bacterium that causes TB, and an estimated 1.6 million people died of the disease in 2005. Currently, TB patients must adhere to a complex treatment regimen over a six- to nine-month period. This demanding schedule often results in patients skipping treatment doses, which has given rise to drug-resistant strains of M. tuberculosis, including multi-drug-resistant (MDR) and, more recently, extensively drug-resistant (XDR) TB.

Approximately one-third of the world's population is infected with Mycobacterium tuberculosis, the bacterium that causes TB, and an estimated 1.6 million people died of the disease in 2005.

Currently, TB patients must adhere to a complex treatment regimen over a six- to nine-month period. This demanding schedule often results in patients skipping treatment doses, which has given rise to drug-resistant strains of M. tuberculosis, including multi-drug-resistant (MDR) and, more recently, extensively drug-resistant (XDR) TB.

SQ109, an antimicrobial agent developed through a partnership between the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, and the biotech company Sequella, Inc., has recently been granted "orphan drug" status by the U.S. Food and Drug Administration and the European Medicines Agency for development against drug-susceptible and drug-resistant TB.

This orphan designation will help accelerate clinical testing of the drug; SQ109 (in combination with other TB drugs) may help establish simpler and more effective treatment regimens for the disease.

Recent events have underscored the immense problem of antimicrobial resistance, including the growing threat of MDR-TB, according to NIAID Director Anthony S. Fauci, M.D. The advancement of SQ109 to a clinical candidate, he says, demonstrates the key role that public-private partnerships can play in developing new interventions to improve public health.

SQ109 was discovered by NIAID scientists in 1999 and developed with grant and contract support from NIAID and contributions by the National Cancer Institute/NIAID Inter-Institute Program for the Development of AIDS-related Therapeutics. NIAID licensed the SQ109 technology to Sequella in March 2006 under a Cooperative Research and Development Agreement.


Story Source:

The above story is based on materials provided by NIH/National Institute of Allergy and Infectious Diseases. Note: Materials may be edited for content and length.


Cite This Page:

NIH/National Institute of Allergy and Infectious Diseases. "Promising New TB Drug Given Special Status By US And European Regulators." ScienceDaily. ScienceDaily, 25 October 2007. <www.sciencedaily.com/releases/2007/10/071025091043.htm>.
NIH/National Institute of Allergy and Infectious Diseases. (2007, October 25). Promising New TB Drug Given Special Status By US And European Regulators. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2007/10/071025091043.htm
NIH/National Institute of Allergy and Infectious Diseases. "Promising New TB Drug Given Special Status By US And European Regulators." ScienceDaily. www.sciencedaily.com/releases/2007/10/071025091043.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pregnancy Spacing Could Have Big Impact On Autism Risks

Pregnancy Spacing Could Have Big Impact On Autism Risks

Newsy (Oct. 1, 2014) A new study says children born less than one year and more than five years after a sibling can have an increased risk for autism. Video provided by Newsy
Powered by NewsLook.com
Robotic Hair Restoration

Robotic Hair Restoration

Ivanhoe (Oct. 1, 2014) A new robotic procedure is changing the way we transplant hair. The ARTAS robot leaves no linear scarring and provides more natural results. Video provided by Ivanhoe
Powered by NewsLook.com
Insertable Cardiac Monitor

Insertable Cardiac Monitor

Ivanhoe (Oct. 1, 2014) A heart monitor the size of a paperclip that can save your life. The “Reveal Linq” allows a doctor to monitor patients with A-Fib on a continuous basis for up to 3 years! Video provided by Ivanhoe
Powered by NewsLook.com
Attacking Superbugs

Attacking Superbugs

Ivanhoe (Oct. 1, 2014) Two weapons hospitals can use to attack superbugs. Scientists in Ireland created a new gel resistant to superbugs, and a robot that can disinfect a room in minutes. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins